Executive record
Alpha ID: alpha:person:atul-dandekarVersion: public-0As of: 2026-10-04
- Executive
Leadership, in context.
Connect capital, control, accountability, and evidence.
Explore the record
ResponsibilitiesInspect board appointments and committee mandates.ExperienceReview career history and qualifications in context.Economic interestsExamine disclosed incentives and ownership.Key Claims
Biography
Mr. Dandekar has served as Chief Strategy and Business Officer since July 2024, previously serving as Chief Strategy Officer from March 2021, and prior to that held various positions at Genentech and Novartis. He is also co-founder of Ollin Biosciences and a director at Broadwing.
Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.
Board service
Board service coverage
No published Claims are available in this section of the public record. This does not establish that the information is undisclosed or that no relevant facts exist.
Review evidence coverageExecutive career
- Current · dates not publishedChief Strategy and Business Officer · Maze Therapeutics, Inc.
- 2026 to end not publishedExecutive title: Chief Strategy and Business Officer · Organization not publishedMAZE DEF 14A executive officers
Claims
Compensation
Compensation coverage
No published Claims are available in this section of the public record. This does not establish that the information is undisclosed or that no relevant facts exist.
Review evidence coverageConflicts and accountability
Alpha has not published independence, related-party, proceedings or disciplinary Claims for this record. This is not a finding that none exist.
Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.
Evidence, history and coverage
Additional published Claims
Published evidence records
2 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.
MAZE DEF 14A executive officers
sec filing · Source published: Apr 28, 2026 · Retrieved: May 4, 2026
Supports 6 claims
- AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 4, 2026
- Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 4, 2026
- Executive company: Executive at Maze Therapeutics, Inc. · Claim reviewed: May 4, 2026
- Executive title: Executive title: Chief Strategy and Business Officer · Claim reviewed: May 4, 2026
- Other Company Role: Atul Dandekar is also linked to Broadwing as Director. · Claim reviewed: May 4, 2026
- Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 4, 2026
Open source
sec def 14a · Source published: Apr 28, 2026 · Retrieved: Sep 6, 2026
Supports 1 claim
- Professional Role: Chief Strategy and Business Officer at Maze Therapeutics, Inc. · Claim reviewed: Sep 6, 2026
No published record changes are available in this projection.
Identity
unclaimed
Evidence
source reported
Evaluation
Unknown
Monitoring
Unknown
Authority
Unknown
Freshness
Observed 2026-10-04
- Biography
- published
- Board service
- not observed
- Executive career
- published
- Education and qualifications
- not observed
- Compensation
- not observed
- Conflicts and accountability
- not observed
- Background screening
- out of scope